Conditions

Atrial Fibrillation (AF)Type 2 Diabetes Mellitus (T2DM)

Keywords

Catheter ablationGlucagon-like Peptide-1 receptor agonistAtrial fibrillationoverweightobesity

Outcome Measures

Primary Outcomes (1)

Atrial fibrillation (AF), atrial flutter (AFL), or atrial tachycardia events lasting ≥30 seconds occurring from the end of a 3-month blanking period post-procedure up to 12 months of follow-up.
at least 12 months of follow-up, beyond the initial 3-month blanking period

Secondary Outcomes (8)

Changes in Body Mass Index (BMI) from baseline to 12 months.
at least 12 months of follow-up, beyond the initial 3 month blanking period
Quality of life assessments.
at least 12 months of follow-up, beyond the initial 3-month blanking period
Complications associated with AF ablation and serious adverse events (such as rehospitalizations, cardiovascular rehospitalizations) occurring during the study period.
at least 12 months of follow-up, beyond the initial 3-month blanking period
Quality of life assessments
at least 12 months of follow-up, beyond the initial 3-month blanking period
Quality of life assessments
at least 12 months of follow-up, beyond the initial 3-month blanking period
+3 more secondary outcomes

Study Arms (2)

Strict Weight Reduction Intervention Group

EXPERIMENTAL

In addition to the routine use of Antiarrhythmic Drugs (AADs) and anticoagulants, the strict weight reduction intervention group also uses GLP-1 receptor agonists for glycemic control and weight loss according to guidelines. This group receives a structured weight loss program, regular nutritional advice in accordance with current guidelines, and physical training assistance over a 12 month period. The intervention plan aims for a total weight loss of 10 kilograms while using GLP-1 receptor agonists.

Drug: Glucagon-like peptide-1 receptor agonists (GLP 1 RA)

Standard Care Group

ACTIVE COMPARATOR

Receives standard glycemic control treatment for diabetes and follows the recommended anticoagulant and antiarrhythmic drug regimens post ablation.

Drug: Glucagon-like peptide-1 receptor agonists (GLP 1 RA)

Interventions

Glucagon-like peptide-1 receptor agonists (GLP 1 RA)Drug

In addition to the routine use of Antiarrhythmic Drugs (AADs) and anticoagulants, the strict weight reduction intervention group also uses GLP-1 receptor agonists for glycemic control and weight loss according to guidelines. This group receives a structured weight loss program, regular nutritional advice in accordance with current guidelines, and physical training assistance over a 12-month period. The intervention plan aims for a total weight loss of 10 kilograms while using GLP-1 receptor agonists.

Standard Care GroupStrict Weight Reduction Intervention Group

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Age \> 18 years. Symptomatic atrial fibrillation (AF) that has been ineffective or intolerable to at least one Class I or III antiarrhythmic drug.
Diagnosed with Type 2 Diabetes Mellitus. Body Mass Index (BMI) greater than 25 kg/m². Ability to understand the purpose of the trial, willingness to participate, and signing of the informed consent form.

Sponsors & Collaborators

Hefei Second People's Hospital
Type not reportedcollaborator
The Third Affiliated Hospital of Anhui Medical University
Type not reportedcollaborator

Study Sites (1)

Shanghai Chest Hospital

Shanghai, China

MeSH Terms

Conditions

Diabetes Mellitus, Type 2Atrial FibrillationOverweightObesity

Interventions

Glucagon-Like Peptide-1 Receptor Agonists

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesArrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic Processes

Study Officials

Xu Liu, Dr
Shanghai Chest Hospital
PRINCIPAL INVESTIGATOR

Strict Weight Management Based on GLP-1 RA for Ablation Outcomes in Overweight or Obese Patients with T2DM and AF

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (8)

Study Arms (2)

Strict Weight Reduction Intervention Group

Standard Care Group

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (8)

Study Arms (2)

Strict Weight Reduction Intervention Group

Standard Care Group

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Source record

Locations